Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Nurses And Midwives Looking For Real Reforms, Australia
The Federal Secretary of the Australian Nursing Federation, Ged Kearney and the Assistant Federal Secretary, Lee Thomas will be available for comment on the Prime Minister"s address on the challenges of Health Reform and the release of the NHHRC report.
generic viagra online
Spectrum Pharmaceuticals Receives Complete Response Letter From FDA For Zevalin
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental Biologics License Application (sBLA) for ZEVALIN® (ibritumomab tiuxetan) in the first-line consolidation setting for non-Hodgkin"s Lymphoma (NHL) patients. The Prescription Drug User Fee Act (PDUFA) Action Date for the ZEVALIN sBLA in the first-line consolidation setting was July 2, 2009. ZEVALIN is currently FDA approved and marketed by Spectrum for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL, including patients who have rituximab-refractory follicular NHL.
News of the day
Serum Bile Acid Profiling For Inflammatory Bowel Disease Characterization
Based on serum bank material, BA profiling was applied in IBD patients and healthy controls which showed that most but not all BA species were decreased to a different extent in CD and UC. BA decreases were highly pronounced in CD patients with surgical interventions in the gut. On the other hand, UC patients with additional liver and gallbladder diseases showed clearly increased levels of those BAs that are synthesized directly in the liver (primary BAs), or subsequently modified by intestinal bacteria (secondary BAs). Furthermore, a marked decrease in the toxic BA lithocholic acid (LCA) was found together with a marked increase in its physiological detoxification product, hyodeoxycholic acid (HDCA), irrespective of the IBD phenotype or clinical manifestation, which showed accelerated detoxification activity in IBD patients. Thus, serum BA profiling might serve as an additional diagnostic tool for IBD characterization and differentiation. In combination with expression profiles of nuclear pregnane X receptor (PXR)-regulated genes, it might allow us to estimate the BA detoxification potential of IBD patients.
Diagnostics

Childhood Radiation Therapy Increases Future Breast Cancer Risk, Study Finds

Women who underwent radiation therapy for cancer as children have an increased long-term risk for developing breast cancer, according to a study published in the Journal of Clinical Oncology, Reuters reports. However, when the childhood treatments included a high dose of radiation to the ovaries, women"s risk of developing future breast tumors was "sharply reduced," according to the study.For the study, Peter Inskip of the National Cancer Institute and colleagues examined 120 women diagnosed with cancer before age 21. All women in the study were treated with radiation between 1970 and 1986 and survived at least five years. The women were compared with four women who also were diagnosed at a young age but did not receive radiation.The study found that the more radiation a woman received as a child, the more likely it was that a tumor would eventually develop. The study did not find that chemotherapy for the first cancer increased the risk for a second cancer (Reuters, 7/20). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009